3 Healthcare Stocks With Long Growth Runways

Three healthcare stocks with long growth runways could lift the sector to greater heights in 2023 and beyond.

| More on:
A doctor takes a patient's blood pressure in a clinical office.

Source: Getty Images

The healthcare sector has performed poorly in recent years, including the COVID year in 2020. Surprisingly, as of this writing, it outperforms all sectors with its 11.95% year-to-date gain.

A reversal of fortune might be on the horizon, especially for growth stocks like Bausch Health Companies (TSX:BHC), Andlauer Healthcare Group (TSX:AND), and Neighbourly Pharmacy (TSX:NBLY).

Extensive product pipeline

Bausch Health develops, manufactures, and markets a range of products in dermatology, gastroenterology, hepatology, neurology, and international pharmaceuticals. It offers a broad range of branded and generic pharmaceuticals, including over-the-counter (OTC) products. Moreover, the global reach extends from North America to several geographic regions.

Current investors delight in the stock’s strong start in 2023 and the 19.53% advance to $10.06 from year-end 2022. Market analysts’ high price target in 12 months is $18.76 — an 86.5% return potential.

The $3.67 billion diversified pharmaceutical company derives health revenues from five segments. According to management, the product pipeline and portfolio expansion reflect Bausch’s commitment to developing innovative products that can help improve people’s lives.

Specialized services

Andlauer Healthcare Group, or AHG, flies under the radar, but it deserves attention following the impressive financial results after three quarters in 2022. Also, at $47.20 per share (-0.32% year to date), this healthcare stock pays a modest 0.59% dividend. Based on market analysts’ forecasts, the price could climb to as high as $60 in 12 months.

In the nine months that ended September 30, 2022, total revenue and net income jumped 57.2% and 53.2% year over year to $482.65 million and $56.45 million, respectively. The top- and bottom-line growth in the third quarter of 2022 were 58.3% and 55.9%. Notably, ground transportation reported the most significant percentage increases in revenue and income.

Its chief executive officer (CEO) Michael Andlauer said, “Our strong growth in revenue and profitability in the quarter and year-to-date reflects the significant impact of our recent acquisitions in both our healthcare logistics and specialized transportation segments.” The full-year 2022 results will come soon, although Andlauer expects to report solid earnings momentum and a strong balance sheet.

AHG takes pride in its robust platform of customized third-party logistics and specialized transportation solutions for the healthcare sector. The $1.97 billion growth-oriented supply chain management company plans to seize further opportunities to expand its North American platform and build value for stakeholders.

Healthcare first

Neighbourly Pharmacy is about community pharmacies and a “healthcare first” strategy that drives performance. The $1.03 billion company desires to be the leader in community healthcare and is on track to achieve that objective. It’s now Canada’s largest and fastest-growing network of independent pharmacies.

Management entered into two binding agreements in October 2022 to acquire eight community pharmacies. The locations of the pharmacies are primarily in smaller, underserved markets, favouring Neighbourly. Apart from generating the bulk of revenues from prescription sales, the competition is less intense.

Neighbourly is also a dividend payer. At $23.30 per share (-0.38% year to date), the dividend yield is 0.77%.

Long growth runways

Bausch Health, Andlauer Healthcare, and Neighbourly Pharmacy have one common denominator: a long growth runway. The companies have catalysts that should propel their stock prices higher in the near term.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Andlauer Healthcare Group. The Motley Fool has a disclosure policy.

More on Dividend Stocks

A worker gives a business presentation.
Dividend Stocks

The Ultimate TSX Stock to Buy With $1,000 Right Now

This top TSX stock seems to be set up to outperform. It pays a nice +5% yield, too!

Read more »

Payday ringed on a calendar
Dividend Stocks

Portfolio Payday: 2 Ultra-High-Yield Monthly Dividend Stocks to Buy in May 2024

Buy these two ultra-high-yield monthly dividend stocks in Canada now for steady passive income.

Read more »

Increasing yield
Dividend Stocks

2 High-Yield Dividend Stocks to Buy as They Bounce

These top dividend stocks still look cheap.

Read more »

ETF chart stocks
Dividend Stocks

The Best Canadian ETFs $100 Can Buy on the TSX Today

These three ETFs are the perfect options for investors looking for growth, income, and a base to hold long term.

Read more »

money cash dividends
Dividend Stocks

TFSA Pension: How to Earn $4,750 Per Year in Tax-Free Income

Here's why the TFSA should be an integral part of your retirement savings strategy.

Read more »

Man considering whether to sell or buy
Dividend Stocks

TELUS Stock: Buy, Sell, or Hold?

TELUS (TSX:T) stock has seen operational improvements but still remains down on a year-over-year basis. So, is it worth it?

Read more »

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

Retirees: 2 Top TSX Dividend Stocks That Still Look Oversold

These great Canadian dividend stocks now offer high yields.

Read more »

edit Balloon shaped as a heart
Dividend Stocks

2 Dirt-Cheap Retail Stocks Fit for Dividend Lovers

Metro (TSX:MRU) and another great retailer that could be ripe for buying in May 2024 for the next three years.

Read more »